List of Excipients in Branded Drug SOLU-CORTEF

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pharmacia & Upjohn Company LLC	SOLU-CORTEF	hydrocortisone sodium succinate	0009-0825	SODIUM PHOSPHATE, DIBASIC
Pharmacia & Upjohn Company LLC	SOLU-CORTEF	hydrocortisone sodium succinate	0009-0825	SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
HF Acquisition Co LLC DBA HealthFirst	SOLU-CORTEF	solu-cortef	51662-1261	SODIUM PHOSPHATE, DIBASIC
HF Acquisition Co LLC DBA HealthFirst	SOLU-CORTEF	solu-cortef	51662-1261	SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

SOLU-CORTEF Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 1, 2026

Solu-Cortef is Pfizer’s injectable hydrocortisone sodium succinate product for intravenous or intramuscular administration. Its commercial position depends less on active-ingredient exclusivity than on manufacturing reliability, emergency-use convenience, vial-and-diluent design, supply continuity, and regulatory execution. The largest opportunities are ready-to-use presentations, lower-volume pediatric formats, improved reconstitution systems, preservative and allergen control, and hospital-focused supply contracts.

What is Solu-Cortef and which excipients does it contain?

Solu-Cortef contains hydrocortisone sodium succinate, a water-soluble corticosteroid prodrug designed for parenteral administration. The product is supplied as a sterile powder, with some presentations using the Act-O-Vial dual-chamber system that separates the drug from the diluent until use.

The FDA-approved label identifies the active ingredient as hydrocortisone sodium succinate equivalent to hydrocortisone and describes the formulation as containing sodium phosphate buffer. The diluent is sterile water for injection in the Act-O-Vial presentation. Exact excipient composition varies by presentation and market, so commercial development should use the current jurisdiction-specific label and approved manufacturing file as the controlling documents. (FDA, 2024a; Pfizer, 2024)

Product attribute	Solu-Cortef profile
Active ingredient	Hydrocortisone sodium succinate
Therapeutic class	Systemic glucocorticoid
Dosage form	Sterile powder for injection
Routes	Intravenous and intramuscular
Main excipient function	Phosphate buffering and pH control
Diluent	Sterile water for injection in dual-chamber presentations
Primary use settings	Emergency medicine, hospitals, surgery, critical care, endocrinology
Reference product sponsor	Pfizer
Regulatory category	Small-molecule drug
Biosimilar pathway	Not applicable
Main competitive factors	Availability, reconstitution speed, container closure, price, hospital contracting

Hydrocortisone sodium succinate is used because native hydrocortisone has limited water solubility. The succinate salt permits rapid preparation of an injectable solution. The excipient system must maintain chemical stability in the dry state, permit rapid dissolution after reconstitution, and avoid unacceptable pH, particulate, or compatibility outcomes.

What excipient strategy supports a hydrocortisone sodium succinate injection?

The core excipient strategy has four requirements: maintain dry-state stability, provide rapid reconstitution, control solution pH, and preserve compatibility with parenteral administration equipment.

Buffer selection and pH control

A phosphate buffer can control pH during manufacture and after reconstitution. The buffer level must be sufficient to limit pH drift without increasing ionic load or creating compatibility issues with infusion solutions.

A follow-on developer should evaluate:

• Initial and post-reconstitution pH.
• Hydrocortisone sodium succinate degradation products.
• Reconstitution time across vial sizes.
• Compatibility with common intravenous fluids.
• Precipitation risk after dilution.
• Container interaction during long-term storage.
• Particulate formation after agitation or transfer.

Phosphate is commercially familiar and generally manageable from a supply perspective. Its presence does not by itself create meaningful differentiation. Differentiation comes from the entire formulation and presentation, including the buffer concentration, powder structure, vial geometry, stopper, reconstitution device, and labeled in-use period.

Lyophilization and powder structure

A sterile powder may be produced by lyophilization or another validated drying process. The powder must dissolve quickly without excessive foaming, clumping, or residual cake. A formulation with a robust cake structure can reduce preparation variability in emergency settings.

Potential formulation tools include:

• Bulking agents to improve cake structure.
• Tonicity modifiers where appropriate.
• pH-adjusting agents.
• Surfactants where interfacial stress or adsorption requires control.
• Chelating agents if trace-metal catalysis contributes to degradation.

Each additional excipient increases regulatory and manufacturing burden. For a mature injectable corticosteroid, a minimal excipient system is commercially attractive because it reduces toxicology work, simplifies labeling, and limits procurement risk.

Preservative strategy

Single-dose, preservative-free presentations are well suited to emergency and hospital use. A multidose format could reduce packaging cost but would introduce preservative exposure, antimicrobial-effectiveness requirements, repeated-entry risks, and additional labeling constraints.

A preservative-free strategy has commercial value in:

• Neonatal and pediatric care.
• Patients with excipient sensitivities.
• Emergency departments.
• Operating rooms.
• Institutional formularies seeking low-excipient products.

The product literature and market-specific labeling must be reviewed for preservatives, sulfites, latex statements, and other formulation or container-closure declarations before making a comparative claim. Excipients and packaging components can differ between U.S. and non-U.S. products.

What formulations are protected by Solu-Cortef?

Solu-Cortef’s commercial identity is associated with hydrocortisone sodium succinate injection and the Act-O-Vial reconstitution presentation. Publicly available FDA materials identify the drug as an established small-molecule injectable rather than a product with current composition-based exclusivity.

Potentially protectable formulation elements include:

1. A specific hydrocortisone sodium succinate-to-buffer ratio.
2. A defined reconstituted pH range.
3. A stability profile under accelerated or stress conditions.
4. A specified residual-moisture range in the powder.
5. A ready-to-use liquid formulation with extended shelf life.
6. A dual-chamber or integrated reconstitution device.
7. A container-closure combination that reduces adsorption or particulate formation.
8. A formulation that remains compatible with selected infusion solutions.

These features could support patent claims only if they produce a non-obvious technical result and satisfy written-description, enablement, and inventiveness requirements. A generic copy of the reference formulation is unlikely to create a durable patent position. A differentiated presentation with measurable stability, handling, or administration benefits has a stronger basis for intellectual-property protection.

When does Solu-Cortef lose exclusivity?

Solu-Cortef is a mature small-molecule product. Its original compound, formulation, and regulatory exclusivity periods have expired. The principal commercial barrier is therefore not originator exclusivity but approval, manufacturing quality, product availability, and contracting.

Exclusivity category	Solu-Cortef position
New chemical entity exclusivity	Expired
Original formulation exclusivity	Expired
Orphan-drug exclusivity	Not the primary product position
Pediatric exclusivity	No current commercial relevance
Biosimilar exclusivity	Not applicable
Orange Book patent barrier	No material current barrier expected based on the mature product profile
Generic pathway	ANDA or another applicable abbreviated pathway, depending on product design

A developer should confirm current Orange Book listings and product-specific regulatory records before relying on the absence of a listed patent. The FDA Orange Book remains the authoritative source for listed patents and exclusivity information for approved products. (FDA, 2024b)

What is the Orange Book status of Solu-Cortef?

Solu-Cortef is an approved small-molecule injectable product, and its competitive pathway is generally associated with abbreviated approval rather than a biosimilar application. The Orange Book analysis should distinguish among:

• Pfizer’s reference-listed drug status.
• Each strength and presentation.
• Act-O-Vial products versus conventional powder vials.
• Hydrocortisone sodium succinate products approved through ANDA pathways.
• Listed patents, if any, associated with a specific product entry.

A generic applicant may face separate regulatory work when its product differs materially from the reference product in reconstitution system, concentration, diluent, container closure, or administration instructions. A device-like dual-chamber presentation can create additional combination-product and human-factors considerations even when the active ingredient is conventional.

Which companies are challenging Solu-Cortef?

The market includes manufacturers of hydrocortisone sodium succinate injection and other injectable hydrocortisone products. Competitive activity is typically driven by generic manufacturers, contract manufacturers, and hospital suppliers rather than by biosimilar developers.

Potential competitor groups include:

• Generic injectable manufacturers with hydrocortisone sodium succinate products.
• Specialty sterile-injectable companies.
• Contract development and manufacturing organizations.
• Hospital distributors and group-purchasing suppliers.
• Developers of ready-to-use emergency corticosteroid products.

The principal competitive challenge is substitution at the formulary and procurement level. Paragraph IV litigation is less likely to be the central risk for a mature product with limited current patent protection. A litigation review should focus on any product-specific patents, ANDA certifications, approval disputes, manufacturing inspections, and supply-related enforcement actions rather than assuming a conventional patent challenge.

What patent litigation affects Solu-Cortef?

No current high-value patent litigation is established here as a material barrier to market entry. The commercial risk profile is more closely tied to regulatory compliance and sterile manufacturing.

Relevant litigation categories would include:

• Patent disputes over a new ready-to-use formulation.
• Patent disputes over an integrated reconstitution device.
• ANDA litigation involving a later-listed formulation or presentation patent.
• Trade-secret claims involving sterile manufacturing processes.
• Contract disputes involving supply, distribution, or private-label manufacturing.
• Product-liability claims involving administration errors or excipient sensitivity.

For a new entrant, patent risk could increase if the product adopts a protected delivery system rather than a conventional powder vial. Freedom-to-operate analysis should cover formulation patents, device patents, container-closure patents, manufacturing-process patents, and use patents in the United States, Europe, Japan, and other major injectable markets.

What method-of-use patents protect hydrocortisone sodium succinate?

Hydrocortisone sodium succinate has broad, established clinical uses, including corticosteroid replacement and treatment of inflammatory, allergic, endocrine, and other acute conditions. Broad method-of-use claims for these conventional uses are unlikely to provide meaningful exclusivity for a generic injectable.

Later method-of-use opportunities could involve:

• A defined dosing protocol in adrenal crisis.
• Use in a specific perioperative or critical-care population.
• A pharmacokinetic or administration regimen.
• Reduced adverse events through a particular infusion rate.
• Combination use with another therapy.
• A pediatric or neonatal dosing method.

Such claims would require a clearly defined clinical benefit and must be separated from routine medical practice already disclosed in labels, guidelines, or published literature. Method-of-use patents may have limited commercial value when hospitals can prescribe the same active ingredient under an alternative label or when enforcement against physicians is impractical.

What commercial opportunities exist for Solu-Cortef excipients and presentations?

The highest-value opportunity is not a new excipient by itself. It is an excipient-and-device package that reduces preparation time, medication error, storage burden, or wastage.

Ready-to-use liquid injection

A stable liquid hydrocortisone sodium succinate product could eliminate reconstitution. The technical barriers are substantial:

• Chemical stability in the liquid state.
• Control of degradation during refrigerated and room-temperature storage.
• Container-closure integrity.
• Compatibility with syringes and infusion lines.
• Particulate control.
• Acceptable osmolality and pH.
• Practical shelf life.

A successful ready-to-use product could command a premium in emergency departments, ambulances, operating rooms, and hospital crash carts. It would compete on workflow efficiency rather than active-ingredient novelty.

Prefilled syringe

A prefilled syringe could reduce preparation steps and dosing errors. The main risks are silicone oil, elastomer compatibility, adsorption, plunger force, extractables and leachables, and stability under transport conditions.

The opportunity is strongest for fixed doses commonly used in emergency protocols. Smaller-volume presentations could target pediatric and outpatient emergency use, although dose flexibility may be lower.

Improved dual-chamber presentation

An improved Act-O-Vial-type system could retain the dry powder while making activation, mixing, and withdrawal easier. Patentable elements may include chamber separation, breakable seals, activation force, visual confirmation, and automated reconstitution.

The product would have to demonstrate a meaningful usability advantage. A minor packaging change may not justify a premium unless it reduces errors or preparation time measurably.

Pediatric and neonatal formats

Pediatric care creates demand for low-dose, preservative-free, low-volume presentations. Commercial advantages could include:

• Reduced wastage.
• Lower withdrawal volume.
• More accurate dosing.
• Fewer vial entries.
• Compatibility with neonatal administration protocols.

The formulation must address adsorption, dead volume, dose accuracy, and container-closure performance at small fill volumes.

Global and low-resource-market products

A robust room-temperature product could have commercial value in markets with unreliable cold-chain infrastructure. A powder presentation already has advantages in this setting, but a developer could pursue:

• Improved thermal stability.
• Longer labeled storage excursions.
• Smaller packaging.
• Simplified reconstitution.
• Regional fill-finish manufacturing.
• Local-language preparation instructions.

The product would need country-specific stability data, pharmacopoeial compliance, and a regulatory strategy for each market.

How strong is the patent estate for Solu-Cortef?

The legacy patent estate is weak as a barrier to conventional generic entry because hydrocortisone sodium succinate injection is an established product with expired originator exclusivity. New patent value is more likely to arise from product architecture than from the active pharmaceutical ingredient.

Asset type	Barrier strength for conventional generic	Opportunity for new entrant
Hydrocortisone sodium succinate composition	Low	Low
Basic powder-for-injection formulation	Low	Low
Phosphate-buffer system	Low to moderate	Limited
Lyophilization process	Low unless narrowly differentiated	Moderate
Ready-to-use liquid formulation	Moderate to high if stability is unexpected	High
Prefilled syringe	Moderate	Moderate to high
Dual-chamber device	Moderate to high	High
Pediatric low-volume presentation	Moderate	Moderate
Manufacturing process	Moderate if secret or technically difficult	Moderate
Broad method of use	Low	Low to moderate

The most defensible patent strategy would combine composition claims, container-closure claims, device claims, and process claims. Patent filings should be made before public disclosure of stability data, device designs, or clinical usability results.

What FDA regulatory pathway applies to new Solu-Cortef competitors?

A conventional hydrocortisone sodium succinate injection may be eligible for an ANDA if it demonstrates pharmaceutical equivalence, bioequivalence where required, equivalent labeling subject to permitted differences, and compliance with applicable chemistry, manufacturing, and controls requirements.

A product with a materially different formulation or presentation may require a 505(b)(2) application. This pathway becomes more relevant when the product is:

• Ready to use rather than reconstituted.
• Supplied in a prefilled syringe.
• Presented in a novel dual-chamber device.
• Formulated at a different concentration.
• Supported by clinical or pharmacokinetic bridging data.
• Labeled for a meaningful new use or administration method.

FDA injectable-drug review places substantial weight on sterility assurance, endotoxin control, particulate matter, extractables and leachables, container-closure integrity, stability, and process validation. FDA’s guidance for injectable drug products and ANDA submissions should be incorporated into the development plan. (FDA, 2014; FDA, 2023)

What generic launch risks exist for Solu-Cortef?

A generic launch can occur without patent litigation but still face significant execution risk.

Manufacturing and supply risks

Sterile injectable manufacturing has a high failure cost. Risks include:

• Aseptic-processing deviations.
• Container-closure failures.
• Particulate contamination.
• Vial or stopper shortages.
• Fill-finish capacity constraints.
• Inspection observations.
• Batch-release delays.
• Shortages of pharmaceutical-grade excipients.

A phosphate buffer is generally not the primary supply constraint. The higher risks are sterile fill-finish capacity, validated lyophilization, specialized dual-chamber components, and compliant elastomers.

Commercial risks

Hospital buyers may treat hydrocortisone sodium succinate as a commodity injectable. Price competition can be intense, and purchasing decisions can depend on:

• Wholesale acquisition cost.
• Contract price.
• Backorder history.
• Presentation compatibility with hospital workflows.
• Formulary interchangeability.
• Distributor service levels.
• Shortage performance.

A conventional generic powder vial may have limited pricing power. A ready-to-use or error-reducing presentation can support differentiated pricing if hospitals can quantify labor savings, lower wastage, and reduced medication errors.

How does Solu-Cortef compare with alternative corticosteroid products?

Product category	Main advantage	Main limitation	Excipient opportunity
Hydrocortisone sodium succinate injection	Familiar emergency corticosteroid with rapid parenteral use	Reconstitution and sterile handling	Ready-to-use, prefilled, pediatric formats
Hydrocortisone sodium phosphate or other soluble salts	Potentially convenient liquid formulation	Different regulatory and clinical profile	Stability and compatibility
Methylprednisolone sodium succinate	Potent alternative for many inflammatory indications	Not clinically interchangeable for every use	Dose-convenient presentations
Dexamethasone sodium phosphate	High potency and often available as liquid	Different glucocorticoid profile	Low-volume prefilled formats
Oral hydrocortisone	Lower administration complexity	Unsuitable when oral absorption is impaired	Liquid and pediatric oral products

Substitution is limited by clinical indication, dose equivalence, onset requirements, route, and institutional protocols. A new Solu-Cortef competitor should not assume that all injectable corticosteroids compete on a simple milligram-for-milligram basis.

What licensing deals could support a Solu-Cortef opportunity?

The most practical licensing targets are platform technologies rather than the hydrocortisone molecule. Potential deal structures include:

• Licensing a dual-chamber vial or syringe platform.
• Contract development of a stable ready-to-use liquid.
• Regional rights for sterile fill-finish.
• Private-label supply to hospital distributors.
• Co-development with an emergency-medicine supplier.
• Acquisition of a specialty injectable manufacturer with approved capacity.
• Licensing of an excipient system with demonstrated liquid-state stability.

A commercial agreement should allocate responsibility for regulatory submissions, device validation, shortage notifications, pharmacovigilance, supply continuity, change control, and patent prosecution. For a mature injectable, manufacturing access may have greater transaction value than an active-ingredient license.

Key Takeaways

• Solu-Cortef is hydrocortisone sodium succinate injection, primarily supplied as a sterile powder with phosphate buffering and, in Act-O-Vial products, sterile water for injection.
• Original active-ingredient and formulation exclusivity has expired.
• Biosimilar risk does not apply because hydrocortisone sodium succinate is a small molecule.
• Conventional generic entry is mainly constrained by sterile manufacturing, regulatory compliance, supply reliability, and hospital contracting.
• The strongest commercial opportunities are ready-to-use liquids, prefilled syringes, improved dual-chamber systems, and pediatric low-volume presentations.
• A new patent estate should focus on formulation stability, device architecture, container closure, manufacturing process, and measurable usability improvements.
• An ANDA may be suitable for a conventional equivalent product; a materially different presentation may require a 505(b)(2) strategy.
• Excipient selection should remain minimal unless an added excipient produces a demonstrated stability, handling, or safety benefit.

FAQs

Can a company market hydrocortisone sodium succinate injection without licensing Pfizer?

Yes. A company may pursue an abbreviated or other applicable FDA approval pathway for a pharmaceutically equivalent product, subject to regulatory requirements and any currently listed, product-specific patents.

Is the Act-O-Vial system itself a commercial moat?

It can be a commercial advantage, but its strength depends on current device patents, manufacturing capability, hospital familiarity, and whether the system reduces preparation errors or time. A new entrant can compete with an improved dual-chamber system or a ready-to-use presentation.

Which excipient has the greatest opportunity in a new Solu-Cortef product?

No single excipient is likely to create substantial value alone. The greatest opportunity is a complete formulation and presentation that provides liquid stability, rapid administration, low particulate burden, and simplified emergency use.

Would a preservative-free Solu-Cortef competitor have market value?

Yes, particularly in pediatric, neonatal, emergency, and hospital settings. The commercial value depends on confirmed labeling, stability, packaging, and procurement advantages over existing single-dose products.

Can a hydrocortisone sodium succinate product receive new method-of-use patents?

Potentially, but broad conventional indications are unlikely to provide strong protection. A viable method-of-use patent would need a specific regimen, patient population, administration method, or demonstrated clinical benefit that is not routine or already disclosed.

References

1. Food and Drug Administration. (2014). ANDA submissions: Content and format of abbreviated new drug applications. U.S. Department of Health and Human Services. https://www.fda.gov/

2. Food and Drug Administration. (2023). Injectable drug products: Current good manufacturing practice guidance and related quality requirements. U.S. Department of Health and Human Services. https://www.fda.gov/

3. Food and Drug Administration. (2024a). Solu-Cortef (hydrocortisone sodium succinate) injection prescribing information. U.S. Department of Health and Human Services. https://dailymed.nlm.nih.gov/

4. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations, 44th edition. U.S. Department of Health and Human Services. https://www.fda.gov/

5. Pfizer Inc. (2024). Solu-Cortef product information. https://www.pfizer.com/